Technical Analysis for GDTC - CytoMed Therapeutics Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -3.85% | |
| Crossed Above 50 DMA | Bullish | -3.85% | |
| Outside Day | Range Expansion | -3.85% | |
| Gapped Down | Weakness | -3.85% | |
| NR7 | Range Contraction | -1.50% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 6 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| Gap Down Partially Closed | about 10 hours ago |
| Gapped Down (Partial) | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/29/2024
CytoMed Therapeutics Limited Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapies Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.25 |
| 52 Week Low | 1.89 |
| Average Volume | 4,307 |
| 200-Day Moving Average | 2.96 |
| 50-Day Moving Average | 2.07 |
| 20-Day Moving Average | 2.02 |
| 10-Day Moving Average | 2.01 |
| Average True Range | 0.09 |
| RSI (14) | 47.64 |
| ADX | 9.83 |
| +DI | 26.60 |
| -DI | 23.07 |
| Chandelier Exit (Long, 3 ATRs) | 1.91 |
| Chandelier Exit (Short, 3 ATRs) | 2.15 |
| Upper Bollinger Bands | 2.14 |
| Lower Bollinger Band | 1.90 |
| Percent B (%b) | 0.41 |
| BandWidth | 11.74 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0077 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.00 | ||||
| Resistance 3 (R3) | 2.00 | 2.00 | 2.00 | ||
| Resistance 2 (R2) | 2.00 | 2.00 | 2.00 | 2.00 | |
| Resistance 1 (R1) | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Pivot Point | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Support 1 (S1) | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Support 2 (S2) | 2.00 | 2.00 | 2.00 | 2.00 | |
| Support 3 (S3) | 2.00 | 2.00 | 2.00 | ||
| Support 4 (S4) | 2.00 |
